Research Study

A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Principal Investigator 
Nasreen Khalil

Overview

Body Locations and Systems 
Scleroderma
ClinicalTrials.gov# 
NCT02745145
Status 
Recruiting
Study Start/End 
Dec 19, 2016 to Dec 31, 2020
Locations 
Vancouver General Hospital
Name/Title 
Giselle Gerdak, Research Coordinator
Phone 
604-875--5091
Email Address 
giselle.gerdak@vch.ca
Purpose of Study 

The purpose of this trial is to compare two doses of abituzumab with placebo and determine whether abituzumab is more effective, safer, will be better tolerated and can provoke better immune response than placebo in the treatment of patients with SSc-ILD who already receive constant doses of mycophenolate.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.